Research programme: cancer immunotherapeutics - Lokon PharmaAlternative Names: LOAd 700; LOAd 713; LoCAR 1; LoCAR 2
Latest Information Update: 17 Jun 2016
At a glance
- Originator Lokon Pharma
- Class CAR-T cell therapies; Gene therapies; Oncolytic viruses
- Mechanism of Action Gene transference; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 16 Jun 2016 Preclinical trials in Cancer in Sweden (unspecified route)
- 15 Mar 2016 Biomarkers information updated